Sitagliptin is an oral medication used in the management of type 2 diabetes mellitus. It contains Sitagliptin Phosphate as its active component and is available in pill form. Common brand names include Januvia and various generic versions. In Hong Kong, Sitagliptin is a prescription-only medication regulated by the Department of Health. It is marketed in strengths of 50 mg and 100 mg per tablet.
Sitagliptin belongs to the class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. By blocking the DPP-4 enzyme, it prolongs the activity of incretin hormones (primarily GLP-1 and GIP). These hormones increase insulin secretion from pancreatic β-cells and decrease glucagon release from α-cells in a glucose-dependent manner. The result is lower blood glucose levels after meals without causing significant hypoglycaemia. Onset of action typically occurs within a few days, while steady-state plasma concentrations are reached after about one week of daily dosing.
Sitagliptin is approved by regulatory agencies (including the U.S. FDA, European EMA, and Hong Kong’s Department of Health) for the treatment of type 2 diabetes mellitus in adults. It may be used:
The medication is intended for patients whose diabetes is not adequately controlled by diet, exercise, and other pharmacologic agents.
Current peer-reviewed evidence does not support routine off-label use of Sitagliptin for conditions outside its approved indication. Any experimental application would require careful medical supervision and adherence to local regulatory guidelines.
Off-label use requires medical supervision and individualized risk assessment.
These reactions are generally mild and transient.
Patients should inform their healthcare provider of all medications, supplements, and herbal products before starting Sitagliptin.
This article provides educational information about Sitagliptin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, Sitagliptin is commonly combined with metformin, sulfonylureas, or insulin to achieve better glycaemic control. Each combination should be individualized by a healthcare professional to avoid hypoglycaemia.
A mild rash may be a benign reaction, but any skin rash that spreads or is accompanied by fever should be reported promptly. Severe reactions like Stevens-Johnson syndrome require immediate medical attention.
Safety data in pregnancy are limited. It should only be used if the potential benefit justifies the potential risk to the fetus, and this decision must be made by the prescribing clinician.
Unlike sulfonylureas, Sitagliptin works in a glucose-dependent manner, reducing the chance of low blood sugar. Compared with insulin, it is taken orally and does not require injection.
Yes, but keep the medication in its original labeled container, carry a copy of the prescription, and be aware of any import restrictions in the destination country.
Any new drug that impacts renal function may necessitate a review of your Sitagliptin dose. Your clinician should reassess kidney function after adding such medications.
Persistent upper abdominal pain, nausea, vomiting, and elevated pancreatic enzymes are warning signs. Seek medical care immediately if these symptoms occur.
Yes, several manufacturers produce generic Sitagliptin tablets in the same 50 mg and 100 mg strengths, meeting the same regulatory standards as the brand product.
Most patients see a reduction in HbA1c of about 0.5-0.8 % after 12 weeks of consistent therapy, though individual responses vary.
Do not flush them down the toilet. Return unused tablets to a pharmacy take-back program or follow local disposal guidelines for medications.
